Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report. This year’s edition reasserts our commitment to advancing pioneering RNAi science and supporting health equity.
In recognition of its continued commitment to and advancement of diversity, equity, and inclusion practices in the workplace and in the communities it proudly serves, KeyBank (NYSE: KEY) has earned the #XX place on the 2023 DiversityInc "Top 50 Companies for Diversity" list.